These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 9223539

  • 1. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045).
    Okuyama S, Chaki S, Yoshikawa R, Suzuki Y, Ogawa S, Imagawa Y, Kawashima N, Ikeda Y, Kumagai T, Nakazato A, Nagamine M, Tomisawa K.
    J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539
    [Abstract] [Full Text] [Related]

  • 2. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Kumagai T, Nakazato A, Nagamine M, Yamaguchi K, Tomisawa K.
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [Abstract] [Full Text] [Related]

  • 3. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL.
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [Abstract] [Full Text] [Related]

  • 4. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.
    Chaki S, Funakoshi T, Yoshikawa R, Okuyama S, Kumagai T, Nakazato A, Nagamine M, Tomisawa K.
    Neuropharmacology; 1999 Aug; 38(8):1185-94. PubMed ID: 10462131
    [Abstract] [Full Text] [Related]

  • 5. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA.
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [Abstract] [Full Text] [Related]

  • 6. Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions.
    Zhang K, Davids E, Tarazi FI, Baldessarini RJ.
    Psychopharmacology (Berl); 2002 Apr; 161(1):100-6. PubMed ID: 11967637
    [Abstract] [Full Text] [Related]

  • 7. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats.
    Abekawa T, Honda M, Ito K, Koyama T.
    Psychopharmacology (Berl); 2003 Sep; 169(3-4):247-56. PubMed ID: 12898123
    [Abstract] [Full Text] [Related]

  • 8. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
    Andersen K, Liljefors T, Hyttel J, Perregaard J.
    J Med Chem; 1996 Sep 13; 39(19):3723-38. PubMed ID: 8809161
    [Abstract] [Full Text] [Related]

  • 9. A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.
    Okuyama S, Kawashima N, Chaki S, Yoshikawa R, Funakoshi T, Ogawa SI, Suzuki Y, Ikeda Y, Kumagai T, Nakazato A, Nagamine M, Tomisawa K.
    Life Sci; 1999 Sep 13; 65(20):2109-25. PubMed ID: 10579464
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo pharmacological profile of 5-[2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl]-4-(4-fluorophenyl)thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic.
    Funakoshi T, Chaki S, Kawashima N, Suzuki Y, Yoshikawa R, Kumagai T, Nakazato A, Kameo K, Goto M, Okuyama S.
    Life Sci; 2002 Aug 09; 71(12):1371-84. PubMed ID: 12127158
    [Abstract] [Full Text] [Related]

  • 11. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.
    Ohmori J, Maeno K, Hidaka K, Nakato K, Matsumoto M, Tada S, Hattori H, Sakamoto S, Tsukamoto S, Usuda S, Mase T.
    J Med Chem; 1996 Jul 05; 39(14):2764-72. PubMed ID: 8709107
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
    Merchant KM, Gill GS, Harris DW, Huff RM, Eaton MJ, Lookingland K, Lutzke BS, Mccall RB, Piercey MF, Schreur PJ, Sethy VH, Smith MW, Svensson KA, Tang AH, Vonvoigtlander PF, Tenbrink RE.
    J Pharmacol Exp Ther; 1996 Dec 05; 279(3):1392-403. PubMed ID: 8968364
    [Abstract] [Full Text] [Related]

  • 13. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.
    De Vry J, Schohe-Loop R, Heine HG, Greuel JM, Mauler F, Schmidt B, Sommermeyer H, Glaser T.
    J Pharmacol Exp Ther; 1998 Mar 05; 284(3):1082-94. PubMed ID: 9495870
    [Abstract] [Full Text] [Related]

  • 14. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY.
    Pharmacol Biochem Behav; 2005 Oct 05; 82(2):361-72. PubMed ID: 16216322
    [Abstract] [Full Text] [Related]

  • 15. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ, Newman-Tancredi A, Rivet JM, Brocco M, Lacroix P, Audinot V, Cistarelli L, Gobert A.
    J Pharmacol Exp Ther; 1997 Jul 05; 282(1):132-47. PubMed ID: 9223549
    [Abstract] [Full Text] [Related]

  • 16. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G.
    J Pharmacol Exp Ther; 1998 Sep 05; 286(3):1341-55. PubMed ID: 9732398
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M, Noda Y, Ochi Y, Furukawa K, Une T, Kurumiya S, Hino K, Karasawa T.
    J Pharmacol Exp Ther; 1993 Jan 05; 264(1):158-65. PubMed ID: 8093723
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).
    Suzuki Y, Funakoshi T, Chaki S, Kawashima N, Ogawa S, Kumagai T, Nakazato A, Komurasaki T, Okuyama S.
    Life Sci; 2002 Oct 18; 71(22):2603-15. PubMed ID: 12354579
    [Abstract] [Full Text] [Related]

  • 19. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine.
    Hertel P, Nomikos GG, Svensson TH.
    Br J Pharmacol; 1997 Dec 18; 122(8):1639-46. PubMed ID: 9422809
    [Abstract] [Full Text] [Related]

  • 20. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.
    Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, Marwood R, Mcallister G, Myers J, Curtis N, Kulagowski JJ, Leeson PD, Ridgill M, Graham M, Matheson S, Rathbone D, Watt AP, Bristow LJ, Rupniak NM, Baskin E, Lynch JJ, Ragan CI.
    J Pharmacol Exp Ther; 1997 Nov 18; 283(2):636-47. PubMed ID: 9353380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.